Wall Street equity analysts tracking Emergent BioSolutions Inc. (NYSE: EBS) maintain a consensus median 12-month price target hovering around $11.00 per share, with individual published forecasts ranging from a low of $10.00 to a high bullish target of $12.00. These figures adjust dynamically following quarterly earnings announcements, regulatory product updates, and updates regarding the company's specialty pharmaceutical and biodefense contracts.